Overexpression of the ERBB2 oncogene, located on chromosome 17q12 and commonly referred to as HER2 (human epidermal growth factor receptor 2), was recognized decades ago as a key factor associated with poor outcome in primary breast cancer (BC)1,2. This evidence concerns the gene ERBB2 and breast carcinoma.